New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing.

Srivastava, Rai Ajit K

New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing.

Srivastava, Rai Ajit K.

Affiliation

Srivastava RAK; Integrated Pharma Solutions, Boston, USA; Northeastern University, Boston, USA. Electronic address: ajitsriva@gmail.com.

Nutr Metab Cardiovasc Dis ; 33(12): 2317-2325, 2023 Dec.

Article in En | MEDLINE | ID: mdl-37805309

Subject(s)

Homozygous Familial Hypercholesterolemia; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Animals; Humans; Hypercholesterolemia/diagnosis; Hypercholesterolemia/genetics; Hypercholesterolemia/therapy; Proprotein Convertase 9/genetics; Proprotein Convertase 9/therapeutic use; Gene Editing; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Angiopoietin-Like Protein 3

Key words

ANGPTL3; Atherosclerosis; CRISPR/Cas9; Hypercholesterolemia; LDL receptor

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / Homozygous Familial Hypercholesterolemia / Hypercholesterolemia Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Nutr Metab Cardiovasc Dis Journal subject: ANGIOLOGIA / CARDIOLOGIA / CIENCIAS DA NUTRICAO / METABOLISMO Year: 2023 Type: Article

Fulltext

XML

PubMed Links

Search on Google